Kantaro Biosciences

Kantaro Biosciences (“Kantaro”) is a joint venture between Mount Sinai and RenalytixAI, to drive rapid innovation and scale-up of rigorous, results-driven and reproducible diagnostic tests for critical health challenges. Kantaro’s groundbreaking antibody test, based on technology developed at Mount Sinai and manufactured in partnership with Bio-Techne, is the one of the first tests capable of identifying the level of an individual’s neutralizing antibodies.

United States


Product Areas


COVID-19 IgG/IgM Show all suppliers